Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Eileen Rillamas-SunMarilyn L KwanCarlos IribarrenRichard ChengRomain NeugebauerJamal S RanaMai Nguyen-HuynhZaixing ShiCecile A LaurentValerie S LeeJanise M RohYuhan HuangHanjie ShenDawn L HershmanLawrence H KushiHeather GreenleePublished in: Breast cancer research and treatment (2023)
Hormone receptor-positive BC survivors treated with AIs may have higher rates of developing diabetes, dyslipidemia, and hypertension over an average 7.8 years post-diagnosis.